vs
Side-by-side financial comparison of ManpowerGroup Inc. (MAN) and TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Click either name above to swap in a different company.
ManpowerGroup Inc. is the larger business by last-quarter revenue ($4.7B vs $4.7B, roughly 1.0× TEVA PHARMACEUTICAL INDUSTRIES LTD). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs 0.6%, a 9.6% gap on every dollar of revenue. On growth, TEVA PHARMACEUTICAL INDUSTRIES LTD posted the faster year-over-year revenue change (11.4% vs 7.1%). TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $168.0M). Over the past eight quarters, TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue compounded faster (11.1% CAGR vs 3.5%).
ManpowerGroup is an American multinational corporation headquartered in Milwaukee, Wisconsin. Founded in 1948 by Elmer Winter and Aaron Scheinfeld, ManpowerGroup is the third-largest staffing firm in the world behind Swiss firm Adecco and Dutch firm Randstad NV. The company provides administrative & support services, professional services, and business services through its four primary brands: Manpower, Experis, Right Management, and ManpowerGroup Solutions.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
MAN vs TEVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.7B | $4.7B |
| Net Profit | $30.2M | $481.0M |
| Gross Margin | 16.3% | 56.4% |
| Operating Margin | 1.7% | 6.4% |
| Net Margin | 0.6% | 10.2% |
| Revenue YoY | 7.1% | 11.4% |
| Net Profit YoY | 34.2% | 321.7% |
| EPS (diluted) | $0.65 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.7B | $4.7B | ||
| Q3 25 | $4.6B | $4.5B | ||
| Q2 25 | $4.5B | $4.2B | ||
| Q1 25 | $4.1B | $3.9B | ||
| Q4 24 | $4.4B | $4.2B | ||
| Q3 24 | $4.5B | $4.3B | ||
| Q2 24 | $4.5B | $4.2B | ||
| Q1 24 | $4.4B | $3.8B |
| Q4 25 | $30.2M | $481.0M | ||
| Q3 25 | $18.0M | $433.0M | ||
| Q2 25 | $-67.1M | $282.0M | ||
| Q1 25 | $5.6M | $214.0M | ||
| Q4 24 | $22.5M | $-217.0M | ||
| Q3 24 | $22.8M | $-437.0M | ||
| Q2 24 | $60.1M | $-846.0M | ||
| Q1 24 | $39.7M | $-139.0M |
| Q4 25 | 16.3% | 56.4% | ||
| Q3 25 | 16.6% | 51.4% | ||
| Q2 25 | 16.9% | 50.3% | ||
| Q1 25 | 17.1% | 48.2% | ||
| Q4 24 | 17.2% | 50.2% | ||
| Q3 24 | 17.3% | 49.6% | ||
| Q2 24 | 17.4% | 48.6% | ||
| Q1 24 | 17.3% | 46.4% |
| Q4 25 | 1.7% | 6.4% | ||
| Q3 25 | 1.4% | 19.7% | ||
| Q2 25 | -0.6% | 10.9% | ||
| Q1 25 | 0.7% | 13.3% | ||
| Q4 24 | 1.6% | -0.7% | ||
| Q3 24 | 1.6% | -1.2% | ||
| Q2 24 | 2.2% | -0.1% | ||
| Q1 24 | 1.5% | -5.7% |
| Q4 25 | 0.6% | 10.2% | ||
| Q3 25 | 0.4% | 9.7% | ||
| Q2 25 | -1.5% | 6.8% | ||
| Q1 25 | 0.1% | 5.5% | ||
| Q4 24 | 0.5% | -5.1% | ||
| Q3 24 | 0.5% | -10.1% | ||
| Q2 24 | 1.3% | -20.3% | ||
| Q1 24 | 0.9% | -3.6% |
| Q4 25 | $0.65 | $0.42 | ||
| Q3 25 | $0.38 | $0.37 | ||
| Q2 25 | $-1.44 | $0.24 | ||
| Q1 25 | $0.12 | $0.18 | ||
| Q4 24 | $0.49 | $-0.19 | ||
| Q3 24 | $0.47 | $-0.39 | ||
| Q2 24 | $1.24 | $-0.75 | ||
| Q1 24 | $0.81 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $871.0M | $3.6B |
| Total DebtLower is stronger | $1.1B | — |
| Stockholders' EquityBook value | $2.1B | $7.9B |
| Total Assets | $9.2B | $40.7B |
| Debt / EquityLower = less leverage | 0.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $871.0M | $3.6B | ||
| Q3 25 | $274.6M | $2.2B | ||
| Q2 25 | $289.8M | $2.2B | ||
| Q1 25 | $395.0M | $1.7B | ||
| Q4 24 | $509.4M | $3.3B | ||
| Q3 24 | $410.9M | $3.3B | ||
| Q2 24 | $468.9M | $2.3B | ||
| Q1 24 | $604.8M | $3.0B |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $468.3M | — | ||
| Q2 25 | $470.3M | — | ||
| Q1 25 | $971.4M | — | ||
| Q4 24 | $929.4M | — | ||
| Q3 24 | $999.7M | — | ||
| Q2 24 | $961.7M | — | ||
| Q1 24 | $968.9M | — |
| Q4 25 | $2.1B | $7.9B | ||
| Q3 25 | $2.0B | $7.3B | ||
| Q2 25 | $2.0B | $6.8B | ||
| Q1 25 | $2.1B | $6.3B | ||
| Q4 24 | $2.1B | $5.4B | ||
| Q3 24 | $2.2B | $6.1B | ||
| Q2 24 | $2.1B | $6.4B | ||
| Q1 24 | $2.2B | $7.3B |
| Q4 25 | $9.2B | $40.7B | ||
| Q3 25 | $8.4B | $39.9B | ||
| Q2 25 | $8.5B | $40.1B | ||
| Q1 25 | $8.0B | $38.4B | ||
| Q4 24 | $8.2B | $39.3B | ||
| Q3 24 | $8.5B | $41.8B | ||
| Q2 24 | $8.5B | $41.3B | ||
| Q1 24 | $8.5B | $42.8B |
| Q4 25 | 0.51× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.46× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $178.9M | $1.2B |
| Free Cash FlowOCF − Capex | $168.0M | $1.0B |
| FCF MarginFCF / Revenue | 3.6% | 21.6% |
| Capex IntensityCapex / Revenue | 0.2% | 3.0% |
| Cash ConversionOCF / Net Profit | 5.92× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $-161.4M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $178.9M | $1.2B | ||
| Q3 25 | $59.8M | $369.0M | ||
| Q2 25 | $-189.6M | $227.0M | ||
| Q1 25 | $-153.2M | $-105.0M | ||
| Q4 24 | $247.6M | $575.0M | ||
| Q3 24 | $83.5M | $693.0M | ||
| Q2 24 | $-137.9M | $103.0M | ||
| Q1 24 | $116.0M | $-124.0M |
| Q4 25 | $168.0M | $1.0B | ||
| Q3 25 | $44.7M | $233.0M | ||
| Q2 25 | $-207.2M | $131.0M | ||
| Q1 25 | $-166.9M | $-232.0M | ||
| Q4 24 | $236.3M | $446.0M | ||
| Q3 24 | $67.4M | $545.0M | ||
| Q2 24 | $-149.8M | $6.0M | ||
| Q1 24 | $104.2M | $-248.0M |
| Q4 25 | 3.6% | 21.6% | ||
| Q3 25 | 1.0% | 5.2% | ||
| Q2 25 | -4.6% | 3.1% | ||
| Q1 25 | -4.1% | -6.0% | ||
| Q4 24 | 5.4% | 10.5% | ||
| Q3 24 | 1.5% | 12.6% | ||
| Q2 24 | -3.3% | 0.1% | ||
| Q1 24 | 2.4% | -6.5% |
| Q4 25 | 0.2% | 3.0% | ||
| Q3 25 | 0.3% | 3.0% | ||
| Q2 25 | 0.4% | 2.3% | ||
| Q1 25 | 0.3% | 3.3% | ||
| Q4 24 | 0.3% | 3.1% | ||
| Q3 24 | 0.4% | 3.4% | ||
| Q2 24 | 0.3% | 2.3% | ||
| Q1 24 | 0.3% | 3.2% |
| Q4 25 | 5.92× | 2.41× | ||
| Q3 25 | 3.32× | 0.85× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | -27.36× | -0.49× | ||
| Q4 24 | 11.00× | — | ||
| Q3 24 | 3.66× | — | ||
| Q2 24 | -2.29× | — | ||
| Q1 24 | 2.92× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAN
| Other | $2.4B | 52% |
| Transferred Over Time | $1.1B | 24% |
| Staffingand Interim | $1.0B | 22% |
| Productsand Services Other | $50.8M | 1% |
| Permanent Recruitment | $37.5M | 1% |
| Outcome Based Solutionsand Consulting | $20.7M | 0% |
| Transferred At Point In Time | $20.4M | 0% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
